NA-Selank vs P21
A side-by-side research comparison of NA-Selank and P21 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | NA-Selank | P21 |
|---|---|---|
| Full name | N-Acetyl Selank (Acetylated Selank) | P21 (CNTF-Derived Tetrapeptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Same tuftsin-derived mechanism as Selank with acetyl group providing protease resistance; modulates GABA, enhances BDNF. | Mimics CNTF neurogenesis-enhancing portion by increasing BDNF and activating PI3K/Akt. Inhibits LIF signaling to selectively promote neural stem cell proliferation. |
| Molecular weight | 793.91 Da | ~450 Da |
| Half-life | ~5-10 minutes (effective 4-6 hours) | 4-6 hours |
| Bioavailability | ~95% intranasal | Moderate (crosses BBB) |
| Typical dose | 200-400 mcg | 50-100 mcg/kg |
| Frequency | 1-2x daily | Daily |
| Route | Intranasal spray | Intranasal or Subcutaneous |
NA-Selank reported benefits
- Enhanced anxiolytic effect
- Improved stability
- Better bioavailability
- Cognitive focus
- Stress resilience
P21 reported benefits
- Hippocampal neurogenesis
- BDNF increase
- Cognitive enhancement
- BBB penetrant
- No appetite suppression
- Dendritic branching
Related comparisons
Research and educational reference only. Not medical advice.